SCHEMBL1378296

SCHEMBL1378296

Cn1c(=O)n(CC(NS(=O)(=O)c2ccc(-c3ccc(Cl)cc3)cc2)C(=O)O)c(=O)c2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 14/20 0.54
ADAMTS5 Q9UNA0 1/20 0.54
MMP9 P14780 12/20 0.51
ADAMTS4 O75173 2/20 0.46
MMP13 P45452 2/20 0.45
MMP8 P22894 1/20 0.45
MMP1 P03956 1/20 0.45
MMP3 P08254 1/20 0.45
MMP7 P09237 1/20 0.45
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1378295 1.00 MMP2 (0.54) MMP2ADAMTS5MMP9ADAMTS4MMP13
SCHEMBL1380883 0.92 MMP2 (0.54) MMP2ADAMTS5MMP9ADAMTS4MMP13
SCHEMBL1377157 0.90 MMP2 (0.52) MMP2ADAMTS5MMP9ADAMTS4MMP13
SCHEMBL1380422 0.89 MMP2 (0.54) MMP2ADAMTS5MMP9ADAMTS4MMP13
SCHEMBL1380421 0.89 MMP2 (0.54) MMP2ADAMTS5MMP9ADAMTS4MMP13
SCHEMBL1380247 0.85 MMP9 (0.54) MMP2MMP9ADAMTS4MMP13MMP8
Hydroxyamine SCHEMBL7536560 0.83 MMP9 (0.55) MMP2MMP9ADAMTS4MMP13MMP8
SCHEMBL1379841 0.83 BMP1 (0.49) MMP2ADAMTS5MMP9MMP1
SCHEMBL1378261 0.82 BMP1 (0.48) MMP2ADAMTS5MMP9MMP1
SCHEMBL1378262 0.82 BMP1 (0.48) MMP2ADAMTS5MMP9MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4750272-B2 2011-08-17 JP claimed
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 EP claimed
US-6277987-B1 FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS NOVARTIS AG (CH) 2001-08-21 US claimed
EP-1053226-A1 SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES Novartis AG (CH) 2000-11-22 EP claimed
WO-1999042443-A1 SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES NOVARTIS AG (CH) 1999-08-26 WO claimed
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 EP disclosed
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 EP disclosed
US-6410580-B1 ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES NOVARTIS AG (CH) 2002-06-25 US disclosed
US-6277987-B1 FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS NOVARTIS AG (CH) 2001-08-21 US disclosed
EP-1053226-A1 SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES Novartis AG (CH) 2000-11-22 EP disclosed
WO-1999042443-A1 SULFONYLAMINO DERIVATIVES WHICH INHIBIT MATRIX-DEGRADING METALLOPROTEINASES NOVARTIS AG (CH) 1999-08-26 WO disclosed